The company's proprietary Modular Antibody Technology enables the rapid discovery and development of bispecific antibodies, which possess the favorable characteristics of traditional monoclonal antibodies without the production challenges often associated with other antibody formats. F-Star is applying its technology to the development of a pipeline of product candidates and has secured funding and support from leading VC investors and strategic corporate investors. The company is committed to working towards a future free from cancer and other serious diseases through the use of tetravalent bispecific antibodies to create a paradigm shift in treatments. F-Star has four second-generation immunooncology therapeutics in the clinic, each directed against some of the most promising IO targets in drug development, including LAG-3 and CD137.